TY - JOUR
T1 - Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
AU - Benson, Al B.
AU - Venook, Alan P.
AU - Al-Hawary, Mahmoud M.
AU - Azad, Nilofer
AU - Chen, Yi Jen
AU - Ciombor, Kristen K.
AU - Cohen, Stacey
AU - Cooper, Harry S.
AU - Deming, Dustin
AU - Garrido-Laguna, Ignacio
AU - Grem, Jean L.
AU - Randolph Hecht, J.
AU - Hoffe, Sarah
AU - Hubbard, Joleen
AU - Hunt, Steven
AU - Hussan, Hisham
AU - Jeck, William
AU - Johung, Kimberly L.
AU - Joseph, Nora
AU - Kirilcuk, Natalie
AU - Krishnamurthi, Smitha
AU - Maratt, Jennifer
AU - Messersmith, Wells A.
AU - Meyerhardt, Jeffrey
AU - Miller, Eric D.
AU - Mulcahy, Mary F.
AU - Nurkin, Steven
AU - Overman, Michael J.
AU - Parikh, Aparna
AU - Patel, Hitendra
AU - Pedersen, Katrina
AU - Saltz, Leonard
AU - Schneider, Charles
AU - Shibata, David
AU - Skibber, John M.
AU - Sofocleous, Constantinos T.
AU - Stotsky-Himelfarb, Eden
AU - Tavakkoli, Anna
AU - Willett, Christopher G.
AU - Williams, Grant
AU - Algieri, Frankie
AU - Gurski, Lisa
AU - Katie Stehman, P. A.C.
N1 - Publisher Copyright:
© 2023 Harborside Press. All rights reserved.
PY - 2023/6
Y1 - 2023/6
N2 - This discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents the most common histologic form of the disease. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary. Primary treatment of perianal cancer and anal canal cancer are similar and include chemoradiation in most cases. Follow-up clinical evaluations are recommended for all patients with anal carcinoma because additional curative-intent treatment is possible. Biopsy-proven evidence of locally recurrent or persistent disease after primary treatment may require surgical treatment. Systemic therapy is generally recommended for extrapelvic metastatic disease. Recent updates to the NCCN Guidelines for Anal Carcinoma include staging classification updates based on the 9th edition of the AJCC Staging System and updates to the systemic therapy recommendations based on new data that better define optimal treatment of patients with metastatic anal carcinoma.
AB - This discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents the most common histologic form of the disease. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary. Primary treatment of perianal cancer and anal canal cancer are similar and include chemoradiation in most cases. Follow-up clinical evaluations are recommended for all patients with anal carcinoma because additional curative-intent treatment is possible. Biopsy-proven evidence of locally recurrent or persistent disease after primary treatment may require surgical treatment. Systemic therapy is generally recommended for extrapelvic metastatic disease. Recent updates to the NCCN Guidelines for Anal Carcinoma include staging classification updates based on the 9th edition of the AJCC Staging System and updates to the systemic therapy recommendations based on new data that better define optimal treatment of patients with metastatic anal carcinoma.
KW - Anus Neoplasms
KW - Biopsy
KW - Carcinoma, Squamous Cell
KW - Humans
KW - Medical Oncology
UR - http://www.scopus.com/inward/record.url?scp=85163141944&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:001020834100012&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2023.0030
DO - 10.6004/jnccn.2023.0030
M3 - Article
C2 - 37308125
SN - 1540-1405
VL - 21
SP - 653
EP - 677
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 6
ER -